Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
TAK-438 Bismuth Drug Interaction Study
Phase 1
Completed
- Conditions
- Helicobacter Pylori
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT02892409
Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients
Phase 3
Completed
- Conditions
- HeartburnGastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 217
- Registration Number
- NCT02873689
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonomous Region, Nan Ning, Guang XI, China
🇨🇳Affilicated Hospital of Guilin Medical University, Hai Kou, Gui Lin, China
Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis
Phase 3
Terminated
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT02873702
- Locations
- 🇨🇳
Binzhou Medical University Hospital, Binzhou, Shandong, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chongqing Three Gorges Central Hospital, Chong Qing, Chong Qing, China
A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease
Completed
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 310
- Registration Number
- NCT02861118
Phase 3 Alogliptin Pediatric Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 152
- Registration Number
- NCT02856113
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood
Phase 4
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Other: Not treated with omega-3-acid ethyl esters
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 53
- Registration Number
- NCT02839902
Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT02824432
Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil
Completed
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 407
- Registration Number
- NCT02822235
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02817516
Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
Phase 3
Completed
- Conditions
- Back PainNeck PainSpasm
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 180
- Registration Number
- NCT02814565
© Copyright 2025. All Rights Reserved by MedPath